Cargando…
Epigenetics of SFRP1: The Dual Roles in Human Cancers
Secreted frizzled-related protein 1 (SFRP1) is a gene that belongs to the secreted glycoprotein SFRP family. SFRP1 has been classified as a tumor suppressor gene due to the loss of expression in various human cancers, which is mainly attributed by epigenetic inactivation via DNA methylation or trans...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072595/ https://www.ncbi.nlm.nih.gov/pubmed/32074995 http://dx.doi.org/10.3390/cancers12020445 |
_version_ | 1783506443101536256 |
---|---|
author | Baharudin, Rashidah Tieng, Francis Yew Fu Lee, Learn-Han Ab Mutalib, Nurul Syakima |
author_facet | Baharudin, Rashidah Tieng, Francis Yew Fu Lee, Learn-Han Ab Mutalib, Nurul Syakima |
author_sort | Baharudin, Rashidah |
collection | PubMed |
description | Secreted frizzled-related protein 1 (SFRP1) is a gene that belongs to the secreted glycoprotein SFRP family. SFRP1 has been classified as a tumor suppressor gene due to the loss of expression in various human cancers, which is mainly attributed by epigenetic inactivation via DNA methylation or transcriptional silencing by microRNAs. Epigenetic silencing of SFRP1 may cause dysregulation of cell proliferation, migration, and invasion, which lead to cancer cells formation, disease progression, poor prognosis, and treatment resistance. Hence, restoration of SFRP1 expression via demethylating drugs or over-expression experiments opens the possibility for new cancer therapy approach. While the role of SFRP1 as a tumor suppressor gene is well-established, some studies also reported the possible oncogenic properties of SFRP1 in cancers. In this review, we discussed in great detail the dual roles of SFRP1 in cancers—as tumor suppressor and tumor promoter. The epigenetic regulation of SFRP1 expression will also be underscored with additional emphasis on the potentials of SFRP1 in modulating responses toward chemotherapeutic and epigenetic-modifying drugs, which may encourage the development of novel drugs for cancer treatment. We also present findings from clinical trials and patents involving SFRP1 to illustrate its clinical utility, extensiveness of each research area, and progression toward commercialization. Lastly, this review provides directions for future research to advance SFRP1 as a promising cancer biomarker. |
format | Online Article Text |
id | pubmed-7072595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70725952020-03-19 Epigenetics of SFRP1: The Dual Roles in Human Cancers Baharudin, Rashidah Tieng, Francis Yew Fu Lee, Learn-Han Ab Mutalib, Nurul Syakima Cancers (Basel) Review Secreted frizzled-related protein 1 (SFRP1) is a gene that belongs to the secreted glycoprotein SFRP family. SFRP1 has been classified as a tumor suppressor gene due to the loss of expression in various human cancers, which is mainly attributed by epigenetic inactivation via DNA methylation or transcriptional silencing by microRNAs. Epigenetic silencing of SFRP1 may cause dysregulation of cell proliferation, migration, and invasion, which lead to cancer cells formation, disease progression, poor prognosis, and treatment resistance. Hence, restoration of SFRP1 expression via demethylating drugs or over-expression experiments opens the possibility for new cancer therapy approach. While the role of SFRP1 as a tumor suppressor gene is well-established, some studies also reported the possible oncogenic properties of SFRP1 in cancers. In this review, we discussed in great detail the dual roles of SFRP1 in cancers—as tumor suppressor and tumor promoter. The epigenetic regulation of SFRP1 expression will also be underscored with additional emphasis on the potentials of SFRP1 in modulating responses toward chemotherapeutic and epigenetic-modifying drugs, which may encourage the development of novel drugs for cancer treatment. We also present findings from clinical trials and patents involving SFRP1 to illustrate its clinical utility, extensiveness of each research area, and progression toward commercialization. Lastly, this review provides directions for future research to advance SFRP1 as a promising cancer biomarker. MDPI 2020-02-14 /pmc/articles/PMC7072595/ /pubmed/32074995 http://dx.doi.org/10.3390/cancers12020445 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Baharudin, Rashidah Tieng, Francis Yew Fu Lee, Learn-Han Ab Mutalib, Nurul Syakima Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title | Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title_full | Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title_fullStr | Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title_full_unstemmed | Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title_short | Epigenetics of SFRP1: The Dual Roles in Human Cancers |
title_sort | epigenetics of sfrp1: the dual roles in human cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072595/ https://www.ncbi.nlm.nih.gov/pubmed/32074995 http://dx.doi.org/10.3390/cancers12020445 |
work_keys_str_mv | AT baharudinrashidah epigeneticsofsfrp1thedualrolesinhumancancers AT tiengfrancisyewfu epigeneticsofsfrp1thedualrolesinhumancancers AT leelearnhan epigeneticsofsfrp1thedualrolesinhumancancers AT abmutalibnurulsyakima epigeneticsofsfrp1thedualrolesinhumancancers |